The Faculty of Health Sciences is currently holding an open competition for an upcoming Tier 2 CRC in Stem Cell Research. Nominees for Tier 2 Chair positions should, at a minimum, be assistant or associate professors, or possess the necessary qualifications to be appointed to these levels and must hold a full-time faculty appointment at McMaster University within the Faculty of Health Sciences. Individuals who have a firm offer of employment in one of these categories to the University that takes effect by July 1, 2019, are also eligible.

The Faculty of Health Sciences is committed to establishing itself as a world leader in the area of hematopoietic stem cell research and cancer, which has been supported through the Stem Cell and Cancer Research Institute. This Tier 2 CRC will be used to strategically support this area of research strength.

The successful candidate will be an established researcher in the area of stem cell biology research and an internationally renowned researcher in the molecular basis of normal stem cell renewal and malignancies associated with the deregulation of normal stem cell biology.

Tier 2 Chairs, tenable for five years and renewable once, are for exceptional emerging researchers, acknowledged by their peers as having the potential to lead in their field. Tier 2 nominees must:

- be excellent emerging world-class researchers who have demonstrated particular research creativity;
- have demonstrated the potential to achieve international recognition in their fields in the next five to ten years;
- as chairholders, have the potential to attract, develop and retain excellent trainees, students and future researchers; and
- be proposing an original, innovative research program of high quality.

Candidates who are more than 10 years from having earned their highest degree and who have had career breaks, such as maternity, parental, or extended sick leave, clinical training, etc., may have their eligibility for a Tier 2 Chair assessed through the program’s Tier 2 justification process. Please contact Tracy Arabski at arabski@mcmaster.ca for more information. Full program information, including further details on eligibility criteria, can be found at the Canada Research Chairs website at http://www.chairs-chaires.gc.ca/program-programme/nomination-mise_en_candidature-eng.aspx. All nominations for CRCs are subject to review and final approval by the CRC Secretariat.

Commitment to Inclusive Excellence: Equity, Diversity and Inclusion Statement:

The diversity of our community and our workforce is integral to and at the core of our innovation and creativity and strengthens our research, teaching and service excellence, as well as our broader learning environment. To achieve this vision for inclusive excellence, McMaster is committed to principles of equity and inclusion. McMaster invites applications from all qualified candidates and particularly welcomes applications from self-identified Indigenous (First Nations, Métis and Inuit) peoples, members of racialized communities (“visible minorities”), persons with disabilities, women and LGBTQ+ persons of marginalized sexual orientation and gender identities.

All qualified candidates are encouraged to apply; however, in accordance with Canadian Immigration requirements, Canadian citizens and permanent residents of Canada will be given priority.

How to apply:

The application and review process requires interested applicants to complete the “Application to be nominated for a
Canada Research Chair™ which reflects all criteria and indicators of success and include a most recent CV. The deadline for submission for this competition is January 30th, 2019. The Dean will have final approval of all recommendations regarding CRC allocations. A CRC review panel will review applications and successful applicants will be invited to complete a full application to CRC. Applicants will be notified of their success and the successful applicant will be asked to submit their CRC application based on the time of the expiry of the CRC as outlined below.

McMaster University recognizes the potential impact that career interruptions and personal circumstances (e.g., pregnancy, early childcare, eldercare, illness, etc.) can have on an applicant’s record of research achievement. We encourage applicants to explain in their applications the impact that career interruptions, or other issues may have had as described under “Career Interruptions” at CRC’s Requirements for recruiting and nominating Canada Research Chairs at http://www.chairs-chaires.gc.ca/program-programme/equity-equite/recruitment-recrutement-eng.aspx. Further detail may be found under Guidelines for Assessing the Productivity of Nominees at http://www.chairs-chaires.gc.ca/peer_reviewers-evaluateurs/productivity-productivite-eng.aspx#career.

Applicants should submit the application to be nominated for a CRC chair, cv, and a statement describing any contributions that the applicant may have made to advancing equity, diversity and inclusion in teaching, learning, research or service within post-secondary, community-based and other professional settings (2 pages maximum).

All applicants must also complete a brief Diversity Survey as part of the application process. This survey can be found at https://surveys.mcmaster.ca/limesurvey/index.php/834664?lang=en and will take approximately two minutes to complete. The questions are voluntary. All information collected is confidential and will be used to support efforts to broaden the diversity of the applicant pool and to promote a fair, equitable and inclusive talent acquisition process.

Job applicants requiring accommodation to participate in the hiring process should contact the Human Resources Service Centre at 905-525-9140 ext. 222-HR (22247) to communicate accommodation needs.

Queries should be addressed to Tracy Arabski, Director, Health Research Services at arabski@mcmaster.ca or ext. 22515.

Alton Ochsner Award Relating Smoking and Disease
The Alton Ochsner Award recognizes outstanding scientific achievements that have provided pivotal insights into the fundamental biological and clinical mechanisms that relate tobacco consumption with disease. This scientific work may be clinical, fundamental, epidemiological, or prevention in scope. The prime criterion for award is its scientific context and impact on this major health threat. All nominations, whatever the category of scientific inquiry, must be supported by letters and copies of peer-reviewed scientific publications as detailed below.

One to three investigators will receive an award of $15,000.

Nominations should be made by a letter describing in detail, but concisely, the scientific work and major contributions of the investigator to the field. Self-nominations are excluded. The nomination packet must also include and be supported by:

1. Nominee’s CV (including active mailing address, office and cell telephone numbers, e-mail address, and bibliography);
2. At least 2 additional supporting letters from scientific peers from outside the candidate’s institution;
3. Reprints of at least 3 pertinent major scientific contributions.

Submissions should be made as PDF attachment(s) sent electronically to the Ochsner Clinic at AOSRA@ochsner.org. Any nominees not receiving the award will automatically be considered for an additional two years. Unsuccessful candidates must wait two years before being re-nominated, after those three years of consideration.

Deadline: March 31, 2019

For more information please contact Danelle D’Alvise at dalvise@mcmaster.ca.

John C. Sibley 2019 Award for Excellence in Education for Part Time Faculty
Background: The John C. Sibley Award is named in honour of Jack Sibley who became Associate Dean, Education in 1979 and was known for his interdisciplinary approach to community health both locally and internationally.
The John C. Sibley award is presented annually to a part-time faculty member in the Faculty of Health Sciences who has contributed in an outstanding manner to the education of health professionals (preferably in more than one sector) (see reverse side for previous winners). The award, which includes a citation and a cheque in the amount of $2500.00 (gross), is presented at a formal meeting of the recipient’s department/school. The names of both the winners and nominees are announced publicly through email and newsletters. A permanent plaque in the 2J area (HSC) serves as a record of the awardees.

**Nomination Guidelines:**

**Nominations are now being requested** for this prestigious award, which highlights the importance of part-time faculty in fulfilling the academic mission. The nominees will be evaluated according to the following criteria:

- Development and evaluation of innovative educational activities in the health sciences
- Support of interprofessional education
- Sustained commitment to the academic mission
- Impact on teaching and learning in FHS programs and initiatives

If you know of an eligible part-time faculty member, we would strongly encourage you to submit a nomination. The nomination package should include an updated CV; a detailed letter by the proposer which addresses each of the above criteria highlighting examples in each area; two supporting letters commenting on the special contributions of the nominee in line with the criteria. Please send appropriate documentation to Dr. Alan Neville, Associate Dean, Health Professional Education and Chair, Sibley Selection Committee to HSC-2E18 or by email mcarthj@mcmaster.ca by **Friday March 22nd, 2019.**


Please submit feedback through the [online form](http://www.cihr-irsc.gc.ca/e/51217.html).

**CIHR PROJECT SPRING 2019 REGISTRATION IS NOW OPEN.** You must register by February 6, 2019 if you wish to submit a full application.

**Webinars on the Project Grant: Spring 2019 Application**

CIHR is holding a series of webinars on the [Project Grant: Spring 2019 application](http://www.cihr-irsc.gc.ca/e/51217.html). These Question and Answer webinars are designed to complement the Project Grant: Spring 2019 Applicant Learning Module, which are available now on the [Learning for Applicants](http://www.cihr-irsc.gc.ca/e/51217.html) web page. Together, the module and webinars will give applicants an insightful understanding of the recent changes to the Project Grant competition and the application submission process.

The Project Grant: Spring 2018 webinars will be held between January 23rd and February 27th. [Register for a webinar now.](http://www.cihr-irsc.gc.ca/e/51217.html)

**Host a Clinical Trials Intern**

Western University’s Clinical Trials Management post-degree diploma is now recruiting hosts and sites for summer practicums. If you are interested in more information, please connect with Katrina McIntosh, Katrina.mcintosh@uwo.ca, 519-661-2111 x85211, or check out further details at [http://hostanintern.uwo.ca](http://hostanintern.uwo.ca).

The Clinical Trials Management program is a one-year post-degree program that includes 9 clinical trials courses and a mandatory practicum. Enrollment is competitive and candidates must have an undergraduate Science or Health Science degree. In order to graduate from the program, students must complete a 400 hour practicum which is scheduled to run from May – August, 2019 (end dates vary based on hours/week at the site, which is flexible).
Invites all faculty to attend Mitacs: Funding Programs and Applying & Finding an Industry Partner

Date: Monday, February 4, 2019  
Time: 1:30pm to 3:30pm  
Location: Council Chambers, GH 111

Mitacs Funding Programs and Applying (approx. 1hr)  
Are you looking for funding? Have you heard of Mitacs but aren’t sure what program is best for you, your students, or how to apply? Hear about Mitacs’ funding research and training programs for undergraduate, graduate students and postdoctoral fellows programs and how these programs could help advance your research.

How to find an Industry Partner (approx. 1hrs)  
Mitacs will describe best practices and tips to finding an industry partner.

If you’re interested in attending, please register at: Mitacs: Programs/Funding & Finding an Industry Partner

Speakers:  
Rebecca Bourque, Director of Strategic Accounts & Business Development - Mitacs  
Ryan Caldwell, Business Development Officer – MILO/Mitacs

My Pitch: Building Research Collaborations  
Date: Thursday, February 21, 2019  
Time: 9:30am to 11am  
Location: University Hall, UH 211

My Pitch: Building Research Collaborations  
Successful researchers explore and build partnerships across many sectors with the goal of developing broad-based, collaborative relationships to help advance industry and social innovation, and their research. Developing and delivering a compelling pitch is a key element to initiating these partnerships.

Mitacs’ Director of Strategic Accounts and Business Development, Rebecca Bourque, will lead this hands-on session to guide you, the researcher, in developing the research-specific story that you would pitch to a prospective partner. Once you have created your narrative, you will practice your pitch, receiving constructive comments to help refine your message and delivery.

To ensure everyone receives one-on-one consultation throughout the workshop, these sessions will be limited to 12 participants.

Please note: participants must arrive to the workshop with their identified potential partner in mind.

If you are interested in attending, please register at: My Pitch

Research Project Management Course at UofT  
Good project management is vital to the success of major research projects. UofT has developed a course specifically tailored for the project management of research projects. The course has been adapted for research project management through the collaboration of an Advisory Group of faculty and staff, the School of Continuing Studies, staff from the Division of the Vice-President, Research & Innovation, and the instructor, Dr. Alison Paprica. Dr. Paprica (Assistant Professor [status] at the U of T Institute of Health Policy, Management & Evaluation), was previously the Director responsible for up to $60 million/year of government research funding and has also led numerous large-scale R&D projects in the private, public and not-for-profit sectors.
The course is designed for faculty researchers, staff scientists, post-doctoral fellows, research coordinators and those interested in a path to management and research leadership. This is the second year the course is being offered. Last year, given demand for the fall course, we mounted an additional section for the winter.

Information and registration can be found at [3382 Project Management for Research](#).

**Invitation for feedback: Prioritizing Future Challenges for Canada**

Canada’s three research granting agencies, the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, the Social Sciences and Humanities Research Council of Canada (CIHR, NSERC, SSHRC), and the Canada Foundation for Innovation, are seeking your expertise to help prioritize which future challenges identified through a recent horizon scan are considered most important for Canada.

Outcomes from this consultation may also be leveraged to support the priorities of the Canada Research Coordinating Committee (CRCC), notably to advance efforts in identifying key emerging research areas. Stakeholders from all four agencies are invited to participate in this consultation. Information on the CRCC’s priorities is available on the CRCC’s website. Building upon the success of SSHRC’s 2014 Imagining Canada’s Future initiative, the granting agencies partnered with Policy Horizons Canada, a federal centre of foresight expertise, to undertake a horizon scan as a first step in identifying future challenges for Canada over the next 10 to 15 years.

Policy Horizons Canada drew on sources from across digital media, academic studies, and foresight projects to identify and analyze change data for its global scan. They also conducted a literature review of over 600 early change indicators, and examined additional materials produced by Policy Horizons Canada, government departments and agencies, and other organizations around the world. These approaches were complemented by an online questionnaire engaging various key networks and foresight communities from more than 60 countries.

The scan has identified 16 future challenges with the potential to shape society in profound ways, and which are all multidisciplinary and require broad collaboration to address. The granting agencies ask that you select one top challenge and explore its possible impacts through a brief survey. For the challenge you select, you will be asked a series of questions. You will have the option of repeating the exercise for a challenge you deem of next-most importance. The granting agencies are inviting input from a variety of individuals across the academic, private, public and not-for-profit sectors, in Canada and internationally. Beyond the 16 challenges identified in the horizon scan, you have the opportunity to identify additional challenges deemed critical to Canada’s future.

By taking part in their brief prioritization exercise, using the Futurescaper crowdsourcing tool, you will help to identify which challenges to consider for possible future programming and/or corporate activities. Once you have reviewed the 16 future challenges, the exercise will take you about 10 to 15 minutes to complete. To begin, please follow this link: [FUTURE CHALLENGES PRIORITIZATION](#)

Results of this foresight exercise will be available by spring 2019. Responses are anonymous, and results will be aggregated to ensure anonymity.

Associated Links:
- [Imagining Canada’s Future initiative](#)
- [Policy Horizons Canada](#)
- [Canada Research Coordinating Committee](#)
- [Social Sciences and Humanities Research Council of Canada](#)
- [Natural Sciences and Engineering Research Council of Canada](#)
- [Canadian Institutes of Health Research](#)
- [Canada Foundation for Innovation](#)

**Compilation of GDPR Guidelines Now Available**

The Office for Human Research Protections has developed a new resource for IRBs, researchers, and sponsors that are involved in human subjects research in Europe. Titled Compilation of European GDPR Guidelines, the document lists the data protection authorities of all European countries that fall under the new E.U. General Data Protection Directive (GDPR). For
each country, the compilation also provides the links to any general GDPR guidances, as well as specific guidances on the topics of Research, Legal Basis, Consent, and International Data Transfer. The new Compilation is available here:
https://www.hhs.gov/ohrp/international/index.html

<table>
<thead>
<tr>
<th>Health Research Grant Competitions</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Programs administered by Health Research Services, unless otherwise indicated. Email: <a href="mailto:hsresadm@mcmaster.ca">hsresadm@mcmaster.ca</a></em></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Funding Opportunity (CIHR)</th>
<th>LOI Deadline</th>
<th>Internal HRS Deadline</th>
<th>Sponsor Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>NEW</em> CIHR – Operating Grant: Cancer Research Society</td>
<td></td>
<td>Jan 30</td>
<td>Feb 13</td>
</tr>
<tr>
<td>CIHR – IHSPR Rising Star Award</td>
<td></td>
<td>Feb 7</td>
<td>Feb 21</td>
</tr>
<tr>
<td>CIHR – IHSPR Article of the Year Award 2019</td>
<td></td>
<td>Feb 7</td>
<td>Feb 21</td>
</tr>
<tr>
<td>CIHR – Joint Canada-Israel Health Research Program</td>
<td>Jan 29</td>
<td>Feb 12</td>
<td>Feb 26</td>
</tr>
<tr>
<td>CIHR – Spring 2019 Project Grant</td>
<td></td>
<td>E-Approval</td>
<td>Feb 6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Feb 26</td>
<td>March 6</td>
</tr>
<tr>
<td>CIHR – Health System Impact Fellowship</td>
<td></td>
<td>March 19</td>
<td>April 2</td>
</tr>
<tr>
<td><em>NEW</em> CIHR – Operating Grant: CEEHRC (Epigenetics) 2019</td>
<td></td>
<td>March 26</td>
<td>April 9</td>
</tr>
<tr>
<td><em>NEW</em> CIHR – Team Grant: Mental Wellness in Public Safety</td>
<td>March 19</td>
<td>Oct 22</td>
<td>Nov 5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Funding Opportunity (Non-CIHR)</th>
<th>LOI Deadline</th>
<th>Internal HRS Deadline</th>
<th>Sponsor Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orthopaedic Trauma Association (OTA): Member Full Research Grant</td>
<td>Jan 28</td>
<td>Feb 11</td>
<td></td>
</tr>
<tr>
<td>Orthopaedic Trauma Association (OTA)/AOTNA: Joint Member Full Research Grant</td>
<td>Jan 28</td>
<td>Feb 11</td>
<td></td>
</tr>
<tr>
<td>Grand Challenges Canada: OPTions Innovation Initiative</td>
<td>Jan 29</td>
<td>Feb 12</td>
<td></td>
</tr>
<tr>
<td>National Multiple Sclerosis Society: Research Grants</td>
<td>Feb 6</td>
<td>Jan 30</td>
<td>Feb 13</td>
</tr>
<tr>
<td>Cures Within Reach &amp; Cure Accelerator Live! Request for Proposals (RFP): Developing World Clinical Repurposing Research Trials</td>
<td>Jan 31</td>
<td>Feb 14</td>
<td></td>
</tr>
<tr>
<td>The Klarman Family Foundation: Eating Disorders Research Grants Program</td>
<td>Jan 31</td>
<td>Feb 14</td>
<td></td>
</tr>
<tr>
<td>World Anti-Doping Agency (WADA): Call for Proposals 2019 Scientific Research Grants</td>
<td>Feb 1</td>
<td>Feb 15</td>
<td></td>
</tr>
<tr>
<td>French Embassy in Canada - Cultural and Scientific Services 2019 Mobility Funding for Researchers</td>
<td>Feb 3</td>
<td>Feb 17</td>
<td></td>
</tr>
<tr>
<td><em>NEW</em> Physiotherapy Foundation of Canada: OrthoCanada Research Award in Neck and Back Rehabilitation and Core Stability</td>
<td>Feb 8</td>
<td>Feb 24</td>
<td></td>
</tr>
<tr>
<td>Cures Within Reach &amp; Cure Accelerator Live! Request for Proposals (RFP): Rare Disease Clinical Repurposing Research Trials</td>
<td>Feb 14</td>
<td>Feb 28</td>
<td></td>
</tr>
<tr>
<td>Aralez Pharmaceuticals Canada Inc &amp; CAAIF Research Grant in Allergic Rhinitis or Urticaria</td>
<td>Feb 14</td>
<td>Feb 28</td>
<td></td>
</tr>
<tr>
<td>2019 CAAIF Food Allergy Research Grant</td>
<td>Feb 14</td>
<td>Feb 28</td>
<td></td>
</tr>
<tr>
<td><em>NEW</em> Simons Foundation Autism Research Initiative (SFARI): 2019 Novel Outcome Measures in ASD</td>
<td>Feb 15</td>
<td>March 1</td>
<td></td>
</tr>
<tr>
<td><em>NEW</em> AGE-WELL Strategic Investment Program (SIP) Accelerator Funding</td>
<td>Feb 15</td>
<td>March 1</td>
<td></td>
</tr>
<tr>
<td>The Kidney Foundation of Canada (KFOC): Allied Health Doctoral Fellowships</td>
<td>March 1</td>
<td>March 15</td>
<td></td>
</tr>
<tr>
<td><strong>The Kidney Foundation of Canada (KFOC): Allied Health Scholarship</strong></td>
<td>March 1</td>
<td>March 15</td>
<td></td>
</tr>
<tr>
<td><strong>Banting Research Foundation: Discovery Award</strong></td>
<td>March 1</td>
<td>March 15</td>
<td></td>
</tr>
<tr>
<td><strong>Canadian Blood Services (CBS): Intramural Research Grant Program</strong></td>
<td>Feb 1</td>
<td>March 18</td>
<td>April 1</td>
</tr>
<tr>
<td><strong>ERS Short-Term Research Fellowship 2019</strong></td>
<td>March 18</td>
<td>April 1</td>
<td></td>
</tr>
<tr>
<td><strong>ERS Clinical Training Fellowship 2019</strong></td>
<td>March 18</td>
<td>April 1</td>
<td></td>
</tr>
<tr>
<td><em><em>NEW</em> Autism Speaks: Grants</em>*</td>
<td>March 6</td>
<td>March 27</td>
<td>April 10</td>
</tr>
<tr>
<td><strong>Weston Brain Institute Rapid Response Parkinson’s &amp; Related Diseases</strong></td>
<td>March 13</td>
<td>July 2</td>
<td>July 16</td>
</tr>
<tr>
<td><strong>Weston Brain Institute Transformational Research Parkinson’s &amp; Related Diseases</strong></td>
<td>March 13</td>
<td>July 2</td>
<td>July 16</td>
</tr>
<tr>
<td><strong>Weston Brain Institute Rapid Response Alzheimer’s &amp; Related Diseases</strong></td>
<td>April 1</td>
<td>July 16</td>
<td>July 30</td>
</tr>
<tr>
<td><strong>Weston Brain Institute Transformational Research Alzheimer’s &amp; Related Diseases</strong></td>
<td>April 1</td>
<td>July 16</td>
<td>July 30</td>
</tr>
<tr>
<td><em><em>NEW</em> Ontario Brain Institute (OBI): Event Funding Program</em>*</td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Crohn’s &amp; Colitis Foundation: IBD Ventures</strong></td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ontario Genomics: Genomic Applications Partnership Program (GAPP)</strong></td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Weston Brain Institute Postdoctoral Scholars at Oxford</strong></td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Weston Brain Institute International Fellowships: Canada</strong></td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Alzheimer’s Drug Discovery Foundation: Drug Discovery Program</strong></td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Alzheimer’s Drug Discovery Foundation: Neuroimaging &amp; CSF Biomarker Development Program</strong></td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>McMaster University, McMaster Institute for Research on Aging (MIRA), Canadian Longitudinal Study on Aging (CLSA): Call for Proposals</strong></td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>McMaster University, McMaster Institute for Research on Aging (MIRA), Labarge Centre for Mobility in Aging (LCMA): Matching Funds for Research Opportunities</strong></td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MITACS Globalink Research Award</strong></td>
<td>Ongoing MALO</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MITACS Accelerate Fellowship</strong></td>
<td>Ongoing MALO</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Weston Brain Institute: Big Ideas</strong></td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Weston Brain Institute: Early Phase Clinical Trials: Canada</strong></td>
<td>Ongoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>OCE Voucher for Innovation and Productivity II (VIP II) Program</strong></td>
<td>Ongoing MALO</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MITACS Accelerate Program</strong></td>
<td>Ongoing MALO</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Funding Opportunity (DoD) (eBRAP account required – must be validated by McMaster prior to any submission) | LOI Deadline | Internal HRS Deadline | Sponsor Deadline |
| Department of Defense (DoD) Joint Warfighter Medical Research Program (JWMRP) | Feb 1 | TBD | TBD |
| Department of Defense (DoD) Peer Reviewed Medical Research Program | March 28 | March 28 | April 11 |
(PRMRP): Discovery Award

Department of Defense (DoD) Peer Reviewed Medical Research Program (PRMRP): Clinical Trial Award
March 14  June 18  July 2

Department of Defense (DoD) Peer Reviewed Medical Research Program (PRMRP): Focused Program Award
March 14  June 18  July 2

Department of Defense (DoD) Peer Reviewed Medical Research Program (PRMRP): Investigator-Initiated Research Award
March 14  June 27  July 11

Department of Defense (DoD) Peer Reviewed Medical Research Program (PRMRP): Technology/Therapeutic Development Award
March 14  June 27  July 11

Department of Defense (DoD) Amyotrophic Lateral Sclerosis Research Program (ALS RP): Therapeutic Development Award
March 22  July 11  July 25

Department of Defense (DoD) Amyotrophic Lateral Sclerosis Research Program (ALS RP): Therapeutic Idea Award
March 22  July 11  July 25

CIHR – Operating Grant: Cancer Research Society
The Cancer Research Society Operating Grants competition is offered to research projects in basic and fundamental, early translational and environment-cancer research. CIHR-ICR is co-funding Operating Grants, that, but are not limited to:

- Fundamental or Early translational research, including preclinical research in the area of breast cancer;
- Research studying the environmental causes of cancer including viruses, pollutants, work environment, lifestyle and diet;
- Support cancer research by Early Career Researchers.

Funding Details: The total amount available for this funding opportunity is $1,920,000, enough to fund 16 grants. Of this amount, ICR and the Cancer Research Society are each providing $960,000. This amount may increase if additional funding partners participate.

The maximum amount per grant is up to $60,000 per year, for 2 years for a total of 120,000 per grant.

- Of the $960,000 available from CIHR:
  - $480,000 is available to fund applications relevant to environmental causes of cancer and prevention;
  - $480,000 is available to fund relevant to breast cancer.

Additional Details
Internal HRS Deadline: January 30, 2019
Sponsor Deadline: February 13, 2019

CIHR – IHSPR Rising Star Award
The CIHR Institute of Health Services and Policy Research (IHSPR) is dedicated to supporting graduate students and post-doctoral Fellows and to recognizing the research excellence and knowledge translation initiatives of these emerging health services and policy researchers at an early stage in their career.

This award is intended to:

- Recognize the excellence of Canadian research and innovative knowledge translation (KT) initiatives of graduate students (e.g. M.D., M.A., M.Sc. and Ph.D.) and post-doctoral fellows studying health services and policy research;
- Recognize research and/or KT contributions for which a graduate student or post-doctoral fellow has had primary responsibility; and
- Promote careers in health services and policy research.

Funding Details: The total amount available for this funding opportunity is $7,500, enough to fund three (3) awards. The maximum amount per award is up to $2,500, consisting of:

- A $1,000 award (preferably used to present research at a scientific meeting or to attend a health services and policy research training program)
- Up to a maximum of $1,500 in travel support to attend the annual Canadian Association of Health Services and Policy Research (CAHSPR) conference (see Additional Information)

The award recipients will also receive:

- Publication of their profile on the IHSPR website and in an IHSPR newsletter
- A certificate of excellence from CIHR-IHSPR

Additional Details
Internal HRS Deadline: February 7, 2019
Sponsor Deadline: February 21, 2019
CIHR – IHSPR Article of the Year Award 2019
This award is intended to recognize published research that has significantly contributed to the advancement of the field of health services and policy research in Canada. IHSPR will consider articles related to:

- Research that demonstrates a clear impact or potential impact on policy or practice (e.g., decision maker uptake, change management for improved practice);
  Or
- Research that breaks ground in the way health services or policy research is conducted (e.g., innovations in methodology, novel theory or application of theory, new approaches to existing problems).

Funding Details: The total amount available for this funding opportunity is $12,000, enough to fund one (1) award, consisting of:

- An award of $10,000
- Up to a maximum of $2,000 in conference registration and travel support (to receive the award and/or deliver an invited talk at a CIHR-IHSPR or partner event – see Additional Information)

Additional Details
Internal HRS Deadline: February 7, 2019
Sponsor Deadline: February 21, 2019

CIHR – Joint Canada-Israel Health Research Program
The Joint Canada-Israel Health Research Program (the Program) seeks to support fundamental research at the cutting-edge of biomedical science. This fifth call for proposals is directed toward basic biomedical sciences in new frontiers in metabolism in health and disease, while building capacity and furthering the knowledge base in low- and middle-income countries.

The Program will support world-class research teams co-led by Canadian and Israeli investigators. The teams will be expected to integrate researchers from low- and middle-income countries (see Appendix A for list of eligible countries) to further their scientific capacity. In their capacity as collaborators or trainees, researchers in eligible countries will contribute to and benefit from their involvement in the Initiative.

Teams are encouraged to integrate sex and gender perspectives into their research, including where relevant Sex- and Gender-Based Analysis (SGBA). SGBA is an approach that systematically examines sex-based (biological) and gender-based (socio-cultural) differences, to promote rigorous science that is sensitive to sex and gender, and has the potential to expand our understanding of health determinants for all people.

Research Areas
The fifth call of this program supports biomedical sciences with special emphasis on new frontiers in metabolism in health and disease. Potential topics may include, but are not limited to the following:

- Cellular and molecular basis of metabolic diseases
- Pathophysiology of metabolic response associated with infectious diseases
- Prevention of metabolic diseases
- Microbiome and metabolism
- Inflammation and metabolism
- Circadian rhythms and metabolism
- Prevention and metabolism
- Lipid, amino acid, and sugar metabolism
- Hormonal regulation of metabolism
- Epigenetics and metabolism
- Aging and metabolism
- Exercise metabolism
- Novel biomarker technologies for metabolites
- Models for metabolic research

Funding Details: The maximum amount per project that can be requested by the Canadian applicant from IDRC is up to CAD $670,000 over 3 years.

Additional Details
LOI/Registration Deadline: January 29, 2019
Internal HRS Deadline: February 12, 2019
Sponsor Deadline: February 26, 2019

CIHR – Spring 2019 Project Grant
The Project Grant program is designed to capture ideas with the greatest potential for important advances in fundamental or applied health-related knowledge, health care, health systems, and/or health outcomes by supporting projects with a specific purpose and a defined endpoint. The best ideas may stem from new, incremental, innovative, and/or high-risk lines of inquiry or knowledge translation approaches. The Project Grant program is expected to:

- Support a diverse portfolio of health-related research and knowledge translation projects at any stage, from discovery to application, including commercialization;
- Promote relevant collaborations across disciplines, professions, and sectors;
- Contribute to the creation and use of health-related knowledge.

Funding Details: The total amount available for CIHR’s 2018-19 Investigator- Initiated Research Programs competitions (Foundation Grant, and Fall 2018 and Spring 2019 Project Grants) is approximately $655M. The allocation of this investment between the Foundation and Project grant programs is under review.

Additional Details and to Register

LOI/Registration Deadline: February 6, 2019 8PM E-Approval on RNet
Internal HRS Deadline: February 26, 2019 - 12PM
Sponsor Deadline: March 6, 2019 - 12PM

CIHR – Health System Impact Fellowship

The Health System Impact (HSI) Fellowship (for doctoral trainees and post-doctoral fellows) provides highly-qualified doctoral trainees and post-doctoral fellows studying health services and policy research (HSPR), or related fields, a unique opportunity to apply their research and analytic talents to critical challenges in health care that are being addressed by health system and related organizations (e.g., public, private for-profit, not-for-profit, and Indigenous health organizations that are not universities) outside of the traditional scholarly setting, and to also develop professional experience, new skills, and networks.

About the Program

The HSI Fellowship provides doctoral and post-doctoral awardees, both referred to as fellows, with a paid experiential learning opportunity within health system and related organizations where they will dedicate the majority of their time towards a co-developed program of work that advances the organization’s impact goals and contributes to improved health system performance. Fellows will be exposed to how the health system and related organizations work, how decisions are made, how research and analytic skills can contribute to an organization’s performance, and the organization’s role in contributing to improved health and health system performance.

The HSI Fellowship contains a stream for doctoral trainees and a stream for post-doctoral fellows:

- Doctoral fellows receive a paid one-year experiential learning opportunity where they are embedded in their health system partner organization for at least 60% of their time focused on an impact-oriented project of direct relevance to their partner organization. The remaining time (up to 40%), is protected to continue with their doctoral program commitments.
- Post-doctoral fellows receive a paid two-year experiential learning opportunity where they are embedded in their health system partner organization for at least 70% of their time focused on their impact-oriented program of work. The remaining time (up to 30%), is protected for academic research.

Flexibility in the time commitment will enable fellows to make meaningful contributions to an organization’s impact goal, become immersed in the culture and operations of the organization, and benefit from mentorship by executive leaders, while also protecting time to continue with doctoral program commitments or post-doctoral academic research with an academic supervisor. This immersion in both the health system and academic communities, and the co-mentorship by a health system leader and an academic supervisor, are unique elements of the HSI Fellowship program.

HSI Fellows’ experiential learning will also be enhanced through two training offerings:

- Professional development training in a core set of enriched competencies (e.g., leadership, negotiation, project management, change management) designed to accelerate their professional growth and better prepare them to embark on a wider range of career paths with greater impact; and
- Participation in a national cohort of HSI Fellows and leaders from academic and health system and related organizations.

Program Motivation

The HSI Fellowship for doctoral trainees and post-doctoral fellows is a core component of a three-pronged multi-year training modernization funding initiative that stems from the Canadian Health Services and Policy Research Alliance’s (CHSPRA’s) Training Modernization Strategy [ PDF (324 KB) - external link ]. The Training Modernization Strategy identifies key strategic directions to modernize university-based HSPR doctoral and post-doctoral training programs for optimized career readiness and impact. The strategy recognizes and addresses the disconnect between the prospective career trajectories of today’s PhD graduates - which are
diverse and which often involve multiple sectors other than the university - and existing PhD training programs that remain predominantly geared towards academic careers. Within health services and policy, the potential contribution of well-prepared PhD graduates to inform health policy and system transformation is considerable. The Training Modernization Strategy outlines a roadmap to harness this potential.

In addition to preparing PhD trainees and post-doctoral fellows with the professional skills, competencies, experiences and networks to make meaningful and impactful contributions to our health system, the HSI Fellowship also aims to build demand and capacity among health system and related employer organizations for PhD talent. The program links health system organizations with a cohort of the country’s rising stars in HSPR and related fields (including, but are not limited to, population health, health economics, artificial intelligence, health policy, public health, epidemiology, gerontology, data science, etc.). In doing so, the program aims to move Canada along the path towards learning health systems.

Overall, the HSI Fellowship blends research and professional competency development with practical, hands on experience that is complemented with unique mentorship, leadership, and capacity strengthening opportunities. It welcomes a diversity of types of projects and programs of work - including applied research, policy analysis, quality improvement, intervention research, surveillance, priority setting and strategic planning, data management/stewardship, and more – as long as the work relates to critical challenges in health care that are being addressed by the organization and that the work contributes to achieving the health system organization’s impact goal. This is the third launch of the program, and examples of previously funded HSI Fellows, their host partner organizations, and programs of work can be found on CIHR’s website.

**Funding Details:** See Additional Details.

**Additional Details**

**Internal HRS Deadline:** March 19, 2019  
**Sponsor Deadline:** April 2, 2019

**CIHR – Operating Grant: CEEHRC (Epigenetics) 2019**

This funding opportunity is expected to:

- Promote the continued coordination and integration of epigenetic and epigenomic research across Canada and internationally  
- Promote the continued coordination and integration of knowledge translation activities across the CEEHRC funded components

**Funding Details:**

- $250,000 per year is available for four years to support the activities of the research consortia.
- $80,000 is available in year 1 of the grant, specifically for the planning, organization and hosting of the 2019 International Human Epigenome Consortium (IHEC) meeting.

**Additional Details**

**Internal HRS Deadline:** March 26, 2019  
**Sponsor Deadline:** April 9, 2019

**CIHR – Team Grant: Mental Wellness in Public Safety**

The overall objectives of the Mental Wellness in Public Safety Team Grant program are expected to:

- Promote interdisciplinary and multi-sectoral collaboration in PTSTI research  
- Promote knowledge dissemination and translation of PTSTI research in the public safety and related contexts  
- Improve the mental wellness and resilience of Canada’s PSP through innovative research  
- Improve understanding of sex and gender differences in the etiology, prevention, diagnosis and treatment for PTSTI among PSPs

**Funding Details:**

- $990,000 is available to support an application relevant to Firefighters  
- $990,000 is available to support an application relevant to Paramedics  
- $990,000 is available to support an application relevant to Police  
- $990,000 is available to support an application relevant to Correctional Services Personnel  
- $3.96 million is available to support four applications relevant to any of the pools above and/or the General Pool – other areas of research related to mental wellness in PSP.

See **Funding Decision** section for further details.

**Additional Details**

**LOI/Registration Deadline:** March 19, 2019
Orthopaedic Trauma Association (OTA): Member Full Research Grant
OTA Member, Full Grant Pre-proposal, the objective: to support any research issue related to musculoskeletal trauma (excluding product development).

**Funding Details:**
- Clinical Research, value: $40,000 per year, maximum 2 years
- Basic Research, value: $25,000 per year, maximum 2 years
- Directed Topic Research, value: $40,000 per year, maximum 2 years, in the following clinical topics:
  - Indications, utilization, and safety of local antibiotic delivery in orthopaedic trauma care
  - Systemic and healing responses to musculoskeletal trauma in the elderly
  - Tissue (bone, muscle, tendon, ligament, cartilage) regeneration and repair after musculoskeletal trauma

**Additional Details**

Orthopaedic Trauma Association (OTA)/AOTNA: Joint Member Full Research Grant
OTA/AOTNA Joint Research Grant, the objective: to support clinical patient-centered outcomes, clinical or basic science musculoskeletal infection.

**Funding Details:** $50,000 per year for a maximum of 2 years.

**Additional Details**

Grand Challenges Canada: OPTions Innovation Initiative
The OPTions Initiative seeks innovative and transformative ideas that have potential to improve access to safe abortion in low- and middle-income countries where there are one or more legal grounds to support it. These ideas could originate from innovators worldwide and across a wide range of disciplines. We are seeking innovations that:

- Increase access to existing abortion products and services for women and girls who have chosen to terminate their pregnancy.
- Develop and test new methods of pregnancy termination that are an improvement over existing methods.

**Funding Details:** Seed grants a maximum of $250,000 for 18-24 months.

**Additional Details**

National Multiple Sclerosis Society: Research Grants
We welcome applications for studies related to multiple sclerosis that may serve to advance our mission of stopping MS progression, restoring function and improving quality of life, and preventing MS. The Society supports fundamental as well as applied studies, non-clinical or clinical in nature, including projects in patient management, care and rehabilitation.

**Funding Details:** Applicants submit a budget per year.

**Additional Details**

Cures Within Reach & Cure Accelerator Live! Request for Proposals (RFP): Developing World Clinical Repurposing Research Trials
Cures Within Reach, a leading non-profit in repurposing research, recently launched a new funding opportunity Request for Proposal (RFP) for clinical repurposing research in the developing world. This RFP will support clinical research that repurposes approved and
available drugs, devices, nutraceuticals and diagnostics. The developing world includes low and lower-middle income countries as defined by the World Bank; see https://data.worldbank.org/products/wdi-maps.

CureAccelerator Live! Rare Disease Event Details:
- Up to five finalists will be selected from the proposals submitted to pitch their repurposing clinical trials at the CureAccelerator Live! event, where event attendees select the winning project
- Event will be held on May 23, 2019 in the Boston area
- Principal Investigators, or their designated and approved co-investigator, must be willing to attend the event and make a live pitch; no travel stipends are available at this time

Funding Details: Up to $50,000 funding available for any disease that primarily impacts patients in the developing world.

Additional Details
Internal HRS Deadline: January 31, 2019
Sponsor Deadline: February 14, 2019
*For More Information, Contact Leigh Wilson, MILO at wilsle@mcmaster.ca or extension 28642*

The Klarman Family Foundation: Eating Disorders Research Grants Program
What we are looking for:
- Proposals that directly investigate the underlying biology of anorexia nervosa, and the questions of how and why it develops and persists
- We encourage human and animal studies that are directly relevant to the disease, and also large-scale studies addressing its genetic basis, building on results from a large, recently completed, Genome-Wide Association Study of ~ 17,000 cases including nearly 13,000 cases from the Anorexia Nervosa Genetics Initiative (ANGI), an initiative of The Klarman Family Foundation

Scientific scope: Research projects that investigate the underlying biology of anorexia nervosa.

Who is eligible:
- Researchers who hold a faculty appointment at a nonprofit academic, medical or research institution in the United States, Canada or Israel
- Researchers with a strong track record in another field who can bring a new approach to anorexia nervosa research are also encouraged to apply

Research topics NOT within the scientific scope of this program:
- Obesity
- Normal feeding behavior and/or negative energy balance
- Behavioral therapy
- Medical complications of eating disorders
- Clinical trials
- Sickness-induced anorexia or other types of anorexia distinct from the psychiatric disease anorexia nervosa

Funding Details: Up to $750,000 over 1 - 3 years.

Additional Details
Internal HRS Deadline: January 31, 2019
Sponsor Deadline: February 14, 2019

World Anti-Doping Agency (WADA): Call for Proposals 2019 Scientific Research Grants
The objective of the Scientific Research Grant is to:
- Support innovative, fact-based research,
- Promote projects regarding development, or optimization of analytical tools for the detection and/or quantification of doping substances or methods,
- Identify new trends in doping, new drugs, new delivery mechanisms, and
- Consolidate the Athlete Biological Passport (ABP), as well as, the pharmacology of prohibited substances and drug cocktails.

Higher priority will be granted to proposals addressing:
- Detection of peptide hormones and growth factors
- Improved window or limits of detection for prohibited substances/methods (e.g., detection of new long-term metabolites, improved methodologies of detection, etc.);
• Autologous blood transfusions; and
• The ABP (e.g., new biomarkers and target analytes of the ABP including its hematological, steroidal and endocrine modules).

Funding Details: Applicants submit a budget for a maximum of 3 years.

Additional Details
Internal HRS Deadline: February 1, 2019
Sponsor Deadline: February 15, 2019

French Embassy in Canada - Cultural and Scientific Services 2019 Mobility Funding for Researchers
The Embassy of France has launched a call for applications to fund the mobility of researchers between Canada and France in 2019. Applicants must be Canadian or French researchers affiliated to laboratories/departments which are part of a Canadian or French University/Research Centre.

Funding Details: 1 return economy-class flight Canada-France or France-Canada. A contribution towards subsistence costs (per diem, for a maximum of three nights).

Additional Details
Internal HRS Deadline: February 1, 2019
Sponsor Deadline: February 15, 2019

Physiotherapy Foundation of Canada: OrthoCanada Research Award in Neck and Back Rehabilitation and Core Stability
The objective of this funding opportunity is to support the development of treatments related to back and neck rehabilitation and core stability, provide seed funding for mainly pilot or feasibility projects, and further develop the art and science of physiotherapy.

The principal investigator must be a member of the Canadian Physiotherapy Association.

The grant may be used to:
• Employ assistants (technical or professional) or student trainees
• Remunerate professional advisors
• Purchase materials and supplies
• Buy and maintain equipment and supplies
• Support field travel costs

Funding Details: Up to $20,000 for 1 year.

Additional Details
Internal HRS Deadline: February 8, 2019
Sponsor Deadline: February 24, 2019

Cures Within Reach & Cure Accelerator Live! Request for Proposals (RFP): Rare Disease Clinical Repurposing Research Trials
Cures Within Reach, a leading non-profit in repurposing research, recently launched a new funding opportunity Request for Proposal (RFP) for clinical repurposing research in any rare disease. This RFP will support clinical research that repurposes approved and available drugs, devices, nutraceuticals and diagnostics. A rare disease is defined by US standards as a condition that impacts fewer than 200,000 people, or by Canadian and European standards as a condition than impacts less than 1 in 2,000 people.

CureAccelerator Live! Rare Disease Event Details:
• Up to five finalists will be selected from the proposals submitted to pitch their repurposing clinical trials at the CureAccelerator Live! event, to be held in Spring/Summer 2019 in a US city, where event attendees select the winning project
• Exact date and location will be announced prior to the submission deadline
• Principal Investigators, or their designated and approved co-investigator, must be willing to attend the event and make a live pitch; no travel stipends are available

Funding Details: Up to $50,000 funding available for rare disease repurposing clinical trials.

Additional Details
Internal HRS Deadline: February 14, 2019
Sponsor Deadline: February 28, 2019
**Aralez Pharmaceuticals Canada Inc & CAAIF Research Grant in Allergic Rhinitis or Urticaria**

Grant applications will be reviewed by an independent panel of reviewers including scientists and clinical experts in the field of allergic rhinitis or urticaria, as well as patient representatives.

In line with the grant’s objective, eligible applications will be ranked based on:

- Specific impact and relevance of project to the understanding of the causes, mechanisms and management of allergic rhinitis or urticaria
- Scientific appraisal of the proposed methodology
- Demonstrated ability of applicant/collaborators to achieve proposed study objectives
- Potential contribution to improving Canada’s overall capacity in the field of allergic rhinitis or urticaria
- The ability of the proposal to be completed within a one-year term

**Funding Details:** 1 grant of $50,000.

**Additional Details**

- **Internal HRS Deadline:** February 14, 2019
- **Sponsor Deadline:** February 28, 2019

---

**2019 CAAIF Food Allergy Research Grant**

Grant applications will be reviewed by an independent panel of reviewers including scientists and clinical experts in the field of food allergy, as well as patient representatives.

In line with the grant’s objective, eligible applications will be ranked based on:

- Specific impact and relevance of project to the understanding of the mechanisms and management of food allergy (including but not limited to its development, persistence, desensitization, remission, diagnosis, clinical manifestation)
- Scientific appraisal of the proposed methodology
- Demonstrated ability of applicant/collaborators to achieve proposed study objectives
- Potential contribution to improving Canada’s overall capacity in the field of food allergy research
- The ability of the proposal to be completed within a one-year term

**Funding Details:** 1 grant of $25,000.

**Additional Details**

- **Internal HRS Deadline:** February 14, 2019
- **Sponsor Deadline:** February 28, 2019

---

**Simons Foundation Autism Research Initiative (SFARI): 2019 Novel Outcome Measures in ASD**

Grants awarded through this request for applications are intended to develop and validate outcome measures that are suitable for use in intervention studies that target the core symptoms of autism spectrum disorder. Such measures should provide objective data with strong psychometric properties, be scalable for use in large, multisite studies, not be unduly burdensome to participants and families, and have evident clinical relevance. They would ideally capture naturalistic rather than laboratory behavior and be applicable to subjects across a wide range of ages and levels of functioning.

**Funding Details:** A maximum $300,000 per year, including indirect costs, for a maximum 3 years.

**Additional Details**

- **Internal HRS Deadline:** February 15, 2019
- **Sponsor Deadline:** March 1, 2019

---

**AGE-WELL Strategic Investment Program (SIP) Accelerator Funding**

Do you have an innovative idea that has the potential for real-world impact at the intersection of technology and aging? AGE-WELL’s SIP Accelerator funding program supports innovative post-discovery projects focused on the commercialization and/or knowledge mobilization of solutions (e.g. technologies, services or policies) aligned with AGE-WELL’s mission and vision.

The program provides:

- Financial support;
- Training opportunities; and
• Strategic mentorship

AGE-WELL is dedicated to the creation of technologies and services that benefit older adults and caregivers. Our aim is to help older Canadians maintain their independence, health and quality of life through technologies and services that increase their safety and security, support their independent living, and enhance their social participation.

**Funding Details:** Up to $40,000 over 12 months.

**Additional Details**

**Internal HRS Deadline:** February 15, 2019  
**Sponsor Deadline:** March 1, 2019

---

**The Kidney Foundation of Canada (KFOC): Allied Health Doctoral Fellowships**

The Kidney Foundation of Canada offers a limited number of fellowships designed to provide for full-time academic and research preparation at the doctoral level. The objective of this program is to promote and enhance the development of nephrology/organ donation allied health investigators in Canada.

**Funding Details:** Up to $31,000 per year and is tenable in Canada or abroad (for programs outside Canada, the applicant must provide a statement indicating the intention to return to Canada).

**Additional Details**

**Internal HRS Deadline:** March 1, 2019  
**Sponsor Deadline:** March 15, 2019

---

**The Kidney Foundation of Canada (KFOC): Allied Health Scholarship**

The purpose of the Allied Health Scholarship award is to assist the student with a demonstrated interest in nephrology/organ donation in pursuing education at the Masters level to promote and enhance the development of nephrology allied health investigators in Canada.

Applicants must meet the following eligibility requirements:

- Serve as a nephrology nurse or technician, social worker, pharmacist, dietitian, transplant coordinator or other allied health professional;
- Have a demonstrated commitment to the area of nephrology or organ donation with an interest in kidney research;
- Preference will be given to applicants with a minimum of two years full time equivalent experience;
- Have Canadian citizenship or landed immigrant status;
- Be accepted in proposed course of full-time or part-time study.

**Funding Details:** See Additional Details.

**Additional Details**

**Internal HRS Deadline:** March 1, 2019  
**Sponsor Deadline:** March 15, 2019

---

**Banting Research Foundation: Discovery Award**

The objective of the Discovery Award is to support outstanding, new investigators (i.e., investigators who are within the first three years of their independent appointment at a university/research institute in Canada) in any area of health and biomedical research.

The award provides seed funding to gather pilot data to enhance competitiveness for other sources of funding.

The application must be accompanied by a letter of nomination from the applicant’s host department or division head that:

1. Confirms all eligibility criteria have been met (review Eligibility at [https://www.bantingresearchfoundation.ca/grants/guidelines/](https://www.bantingresearchfoundation.ca/grants/guidelines/))
2. Details the operating and the institutional start-up funds available to the applicant;
3. Confirms the candidate has been provided the space and access to institutional infrastructure necessary to conduct the proposed research;
4. Details a mentorship plan, including the name of a mentor, who will assist the applicant in launching their career by a) providing guidance with formulating research proposals, and b) defining career goals and the timelines required to achieve them.

A department/division head will be permitted to nominate only one potential applicant during each annual granting cycle.

**Funding Details:** Maximum $25,000 for 1 year from July 1, 2019 to June 30, 2020.

**Additional Details**
Canadian Blood Services (CBS): Intramural Research Grant Program

The Canadian Blood Services Intramural Research Grant program supports collaborative research projects that will generate knowledge and lead to new discoveries that will improve the safety and efficacy of blood products and the blood system in general. Applicants are required to be affiliated with a Canadian academic program as a faculty member; however, the applicant does not need to be affiliated with Canadian Blood Services. In addition, project teams must include two investigators and at least one investigator must be affiliated with Canadian Blood Services as a scientist, adjunct scientist, or medical director/officer/consultant.

Funding Details: Maximum of $200,000 per year for 2 years.

Additional Details

LOI Deadline: February 1, 2019
Internal HRS Deadline: March 18, 2019
Sponsor Deadline: April 1, 2019

ERS Short-Term Research Fellowship 2019

Short-Term Research Fellowships are established to enable young scientists and clinicians in the early-stages of their research career in respiratory medicine to visit a Host Unit in a country other than the candidate's own, with the aim of learning a research technique not available in the Home Unit. The research training should benefit the Home Unit when the applicant returns there, by leading to research developments and activities back onsite.

Funding Details: Subsistence monthly rate - €2,900. Child allowance (monthly rate per child) - €380. See additional details for more information.

Additional Details

Internal HRS Deadline: March 18, 2019
Sponsor Deadline: April 1, 2019

ERS Clinical Training Fellowship 2019

ERS Clinical Training Fellowships enable members in the early stages of their careers in respiratory medicine to visit a host institution in a European country other than their own to learn a skill or procedure not available at their home institution. This medical training should benefit the home institution when the successful applicant returns there.

Funding Details: Subsistence monthly rate - €2,900. Child allowance (monthly rate per child) - €380. See additional details for more information.

Additional Details

Internal HRS Deadline: March 18, 2019
Sponsor Deadline: April 1, 2019

Autism Speaks: Grants

We are seeking novel grant applications to increase our basic understanding of autism – from genetics to behavior – by analyzing important datasets generated by Autism Speaks through its many programs and partnerships (see below). Applications that co-analyze both Autism Speaks and non-Autism Speaks datasets in combination are encouraged. However, these grants are not for collecting new data but are to give researchers support to investigate new hypotheses or relationships using these datasets. These autism-specific datasets include the Autism Genetics Research Exchange (AGRE) and MSSNG genetics resource (pronounced “Missing” to represent information we are missing to understand autism.

AGRE (research.agre.org) is a dataset housing phenotypic data and biomaterials from AGRE-participating families, most of whom have two or more children on the autism spectrum. This resource not only houses rich phenotypic data, it is a biorepository of blood and/or cells from affected individuals and family members. All families had blood collected from at least one parent and siblings affected with ASD. Data is from 1,736 families with 3348 affected individuals with ASD, including some 1,271 multiplex families. Additionally, the dataset includes clinical and biomaterial data available on over 500 twin families with zygosity testing. Most families had fragile X testing by a CLIA-accredited lab. Reliable, UMACC Certified ADI and ADOS raters collected phenotypic data. They completed ADIs for every family and collected additional phenotypic data that frequently included ADOS, Vineland, Raven’s, PPV, Stanford-Binet assessments and other demographic information. More than 1,700 whole genome sequences from AGRE biosamples are included in the MSSNG dataset.
MSSNG (https://research.mss.ng/) is a groundbreaking collaboration between Autism Speaks, Google, Verily, DNAstack and Hospital for Sick Children/University of Toronto to create one of the world’s largest whole genome database on autism spectrum disorder with insightful phenotypic information about individuals with ASD and their family members. A new version of MSSNG (DB6) will be rolled out in early 2019, to coincide with the launching of this new grant program to use high-quality whole genome sequencing of blood DNA (minimum 30x high-quality coverage) of approximately 10,000 individuals from families from AGRE repository and other important, well-phenotyped cohorts. (See above.) The MSSNG database, built using the Google Cloud Platform and Google Genomics, intends to make its data as useful and widely accessible to researchers as possible, including supporting access to local compute and storage resources, and providing genomic exploration tools for standard and custom analyses. Within the database there are 1,500+ simplex families and greater than 650 multiplex families, amounting to 7,321 WGS, in which 3,446 are from people on the autism spectrum. In early 2019, approximately 2,700 addition WGS will be added to the database to expand this free resource. MSSNG’s philosophy is to promote and enable “open science” research to lead to a better understanding of autism.

The goal of this Request for Applications (RFA) is to advance our understanding of the molecular underpinnings of ASD and how these changes relate to behavioral outcomes and might be assessed as autism subtypes. A successful application will require the use of at least one of these two resources as the primary source of data to be analyzed to support the hypothesis proposed. Other non-Autism Speaks datasets can be co-analyzed to allow larger dataset to be studied in aggregate. We invite a wide variety of proposals to use these Autism Speaks datasets to advance our understanding of ASD risk by exploring novel hypotheses, new genetic-phenotypic relationships and new science to support clinical assessments or treatments.

Grant proposals using AGRE and/or MSSNG datasets can include, but are not exclusive to developing methods to: identify ASD subtypes, advance our understanding of how genetics can improve diagnostic certainty, enable earlier diagnosis and/or deepen understanding of genetic pathways in ways that could lead to identifying targets for improved treatments and health outcomes. Finally, an important goal this program is to bring early career investigators to autism genetics and have them explore MSSNG resources. Additionally, we encourage investigators from other fields to apply.

**Funding Details:** A maximum of $100,000 for 1 year.

**Additional Details**

**LOI Deadline:** March 6, 2019  
**Internal HRS Deadline:** March 27, 2019  
**Sponsor Deadline:** April 10, 2019

---

**Weston Brain Institute Rapid Response Parkinson’s & Related Diseases**

The Weston Brain Institute (the “Institute”) supports research that accelerates the development of therapeutics for neurodegenerative diseases of aging. To help achieve this, the Institute addresses gaps and inefficiencies in the funding market by supporting high-risk, high-reward translational projects, while leveraging world-class business and scientific expertise in a fast and flexible granting process. Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. Diseases such as Alzheimer’s and Parkinson’s are placing a large and increasing burden on society. If ignored, the social and economic costs to manage these diseases will rise significantly within a generation. Meeting this challenge requires pioneering approaches to accelerating treatments. The Rapid Response: Canada program was created to provide seed funding to catalyze novel, high-risk, high-reward, translational research.

Projects must meet two conditions to be eligible:

- Be translational research that helps accelerate the development of therapeutics for neurodegenerative diseases of aging
- Be the development of a therapeutic and/or tool

**Funding Details:** A max of $300,000 over up to 18 months per project.

**Additional Details**

**LOI Deadline:** March 13, 2019  
**Internal HRS Deadline:** July 2, 2019  
**Sponsor Deadline:** July 16, 2019

---

**Weston Brain Institute Transformational Research Parkinson’s & Related Diseases**

The Weston Brain Institute (the “Institute”) supports research that accelerates the development of therapeutics for neurodegenerative diseases of aging. To help achieve this, the Institute addresses gaps and inefficiencies in the funding market by supporting high-risk, high-reward translational projects, while leveraging world-class business and scientific expertise in a fast and flexible granting process. Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. Diseases such as Alzheimer’s and Parkinson’s are placing a large and increasing burden on society. If ignored, the social and...
economic costs to manage these diseases will rise significantly within a generation. Meeting this challenge requires pioneering approaches to accelerating treatments. The Transformational Research Program was created to provide significant support for larger, longer projects.

Projects must meet the following conditions to be eligible:

- Be translational research (excluding clinical trials and clinical trial sub-studies) that accelerates the development of therapeutics for neurodegenerative diseases of aging.
  - Clinical trials and clinical trial sub-studies should be submitted to the Early-Phase Clinical Trials or Rapid Response programs; however other translational research using humans or human samples/data is in scope.
- Be the development of a therapeutic and/or tool and/or complementary approaches

**Funding Details:** A max of $1,500,000 over a max of 3 years.

**Additional Details**

**LOI Deadline:** March 13, 2019  
**Internal HRS Deadline:** July 2, 2019  
**Sponsor Deadline:** July 16, 2019

---

**Weston Brain Institute Rapid Response Alzheimer’s & Related Diseases**

The Weston Brain Institute (the “Institute”) supports research that accelerates the development of therapeutics for neurodegenerative diseases of aging. To help achieve this, the Institute addresses gaps and inefficiencies in the funding market by supporting high-risk, high-reward translational projects, while leveraging world-class business and scientific expertise in a fast and flexible granting process. Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. Diseases such as Alzheimer’s and Parkinson’s are placing a large and increasing burden on society. If ignored, the social and economic costs to manage these diseases will rise significantly within a generation. Meeting this challenge requires pioneering approaches to accelerating treatments. The Rapid Response: Canada program was created to provide seed funding to catalyze novel, high-risk, high-reward, translational research.

Projects must meet two conditions to be eligible:

- Be translational research that helps accelerate the development of therapeutics for neurodegenerative diseases of aging
- Be the development of a therapeutic and/or tool

**Funding Details:** A max of $300,000 over up to 18 months per project.

**Additional Details**

**LOI Deadline:** April 1, 2019  
**Internal HRS Deadline:** July 16, 2019  
**Sponsor Deadline:** July 30, 2019

---

**Weston Brain Institute Transformational Research Alzheimer’s & Related Diseases**

The Weston Brain Institute (the “Institute”) supports research that accelerates the development of therapeutics for neurodegenerative diseases of aging. To help achieve this, the Institute addresses gaps and inefficiencies in the funding market by supporting high-risk, high-reward translational projects, while leveraging world-class business and scientific expertise in a fast and flexible granting process. Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. Diseases such as Alzheimer’s and Parkinson’s are placing a large and increasing burden on society. If ignored, the social and economic costs to manage these diseases will rise significantly within a generation. Meeting this challenge requires pioneering approaches to accelerating treatments. The Transformational Research Program was created to provide significant support for larger, longer projects.

Projects must meet the following conditions to be eligible:

- Be translational research (excluding clinical trials and clinical trial sub-studies) that accelerates the development of therapeutics for neurodegenerative diseases of aging.
  - Clinical trials and clinical trial sub-studies should be submitted to the Early-Phase Clinical Trials or Rapid Response programs; however other translational research using humans or human samples/data is in scope.
- Be the development of a therapeutic and/or tool and/or complementary approaches

**Funding Details:** A max of 1,500,000 over a max of 3 years.

**Additional Details**

The objective of the Applied Research Competition is to 1) support studies that expand the body of knowledge related to autism intervention and treatment, 2) produce practical and clearly objective results, 3) impact public policy, and 4) provide outcomes that offer to enhance quality of life for persons with autism, and their families.

The OAR has placed an emphasis on research that addresses the following targeted areas:

- Community-Based Assessment and Intervention for Challenging Behavior.
- Effectiveness of Augmentative Communication Systems.
- Improving Access to and Effectiveness of Existing Systems and Services.
- Integrated Employment.
- Intersectionality, Equity and Diversity.
- Mental Health Assessment and Intervention.
- Mid-life and Older Adults.
- Residential/Community Services and Supports.

Funding Details: A maximum of $40,000 over 1-2 years.

Additional Details
Pre-Proposal Deadline: March 25, 2019
Internal HRS Deadline: July 22, 2019
Sponsor Deadline: August 5, 2019

Ontario Brain Institute (OBI): Event Funding Program

The Ontario Brain Institute (OBI) is committed to working together with brain health-related organizations in order to increase the capacity of their work in Ontario. The program especially looks to support events that embody OBI’s principles of integration and collaboration.

Funding Details: Up to $5,000.

Additional Details
Sponsor Deadline: Applications are being accepted on a rolling basis in January, May and September.

Crohn’s & Colitis Foundation: IBD Ventures

Is your organization engaged in the discovery or development of a novel product with the potential to help patients with inflammatory bowel diseases? If so, we want to hear from you!

The Crohn's & Colitis Foundation seeks to accelerate the development of products that aim to improve the quality of life of patients with inflammatory bowel diseases. Toward that end, the Foundation has launched IBD Ventures, a new program and dedicated funding mechanism to support product-oriented research and development. Companies and academic investigators can apply.

Funding Details: Up to $500,000 per project per year will be considered. In addition, funded programs will be offered accelerator resources and advising.

Additional Details
Sponsor Deadline: Applications are being accepted on a rolling basis.

Ontario Genomics: Genomic Applications Partnership Program (GAPP)

The Genomic Applications Partnership Program (GAPP) funds downstream research and development (R&D) projects that address real world opportunities and challenges defined by “Receptor” organizations such as industry, government, or not-for-profit entities. These organizations should be committed to commercializing or implementing the outcomes of the project.

Projects are led by the Receptor organization (Canadian or international) but are active collaborations with a Canadian academic researcher. These projects are co-funded by Receptors and other stakeholders and must have the potential to generate significant social and/or economic benefits for Canada.

The GAPP aims to:

- Accelerate the application of Canadian genomics-derived solutions from academia to real-world opportunities and challenges defined by industry, not-for-profit and public-sector Receptors.
- Channel Canada’s genomics capacity into sustainable innovations that benefit Canadians.
- Enhance the value of Canadian genomics technologies by de-risking and incentivizing follow-on investment from industry and other partners.
- Foster mutually beneficial collaboration and knowledge exchange between Canadian academia and technology receptors.

**Funding Details**: 1/3 investment from Genome Canada, 1/3 provided by the Receptor partner (cash and/or in-kind) and 1/3 of other co-funding (non-Genome Canada). For more information see Section 9 and Appendix 2 of the [GAPP Investment Strategy and Guidelines](#).

**Additional Details**

**LOI Deadline**: Accepted on a rolling basis February 19, May 20.

**Weston Brain Institute Postdoctoral Scholars at Oxford**
The Weston Brain Institute Postdoctoral Scholars at Oxford program supports top-tier Canadian postdoctoral scholars by providing international training at the University of Oxford and affiliation with Merton College. Prior to submitting an application, candidates should independently identify a host lab and potential supervisor at the University of Oxford who agrees to supervise them if awarded. Awardees will receive salary support for their postdoctoral positions at Oxford.

**Funding Details**: £57,000 per year (£44,000 per year + benefits) for 2 years.

**Additional Details**

**Sponsor Deadline**: Applications are being accepted on a rolling basis, until 2 positions at a time are filled.

**Weston Brain Institute International Fellowships: Canada**
Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. If ignored, the social and economic costs of managing these diseases will continue to rise. Meeting these challenges requires pioneering approaches to accelerating treatments. The Weston Brain Institute is pleased to launch our International Fellowships: Canada program. The program will support top Canadian PhD students to travel to and work in world-renowned international labs for up to 12 months, to further their translational research on neurodegenerative diseases of aging.

**Funding Details**: $60,000 per year, prorated at $5,000 per month to fit shorter travel and specific project needs.

**Additional Details**

**Sponsor Deadline**: Applications are being accepted on a rolling basis.

**Alzheimer’s Drug Discovery Foundation: Drug Discovery Program**
The Alzheimer’s Drug Discovery Foundation (ADDF) has long recognized the need to bridge the translational funding gap between early-stage drug discovery and clinical development for Alzheimer’s disease, related dementias, and cognitive aging by supporting promising therapeutic approaches.

The Drug Discovery RFP supports:

- Novel drug programs aiming to advance novel lead molecules to the clinical candidate selection stage. This includes small molecules and biologics (e.g., antibodies, peptides, gene therapies).
- Repurposed/repositioned programs aiming to build preclinical evidence in relevant animal models for repurposed drugs (existing drugs that are approved for other diseases and conditions) and repositioned drugs (existing drugs that have entered clinical trials for other indications and have not yet been approved).

**Funding Details**: $150,000-$600,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. One year with potential for follow-on funding. Multi-year proposals can be considered.

**Additional Details**

**LOI Deadline**: Accepted on a rolling basis January 18, April 12, July 12, October 11.
**Sponsor Deadline**: Accepted on a rolling basis February 8, May 10, August 9, November 8.

**Alzheimer’s Drug Discovery Foundation: Neuroimaging & CSF Biomarker Development Program**
Given the pathological heterogeneity of Alzheimer’s disease and related dementias, new biomarkers are needed to more accurately characterize specific underlying pathophysiology.

This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use (see below) that include but are not limited to:

- Clearly demonstrate target engagement for novel therapeutics

  The development of biomarkers that can serve as measures of target engagement for novel targets such as
neuroinflammation features (e.g. microglial activity, cytokine production, astrocytic activity), synaptic damage, metabolic activity, mitochondrial dysfunction, vascular health and epigenetic changes, among others, are of particular interest. High priority will be given to projects developing biomarkers that can be used in combination with therapies currently in development and serve as companion biomarkers.

- Detect signs of disease earlier and monitor progression
  We are seeking programs developing sensitive biomarkers that can detect disease earlier than currently available tests. This includes biomarkers that can predict and monitor conversion from cognitively healthy to mild cognitive impairment (MCI) or MCI to Alzheimer’s disease. We also seek prognostic markers that can predict rates of cognitive decline.

- More accurately diagnose and distinguish between dementia subtypes
  Many types of dementias can present with similar clinical features, and patients often show overlapping pathologies. At present, it is challenging to distinguish between dementia subtypes. Biomarkers that can distinguish between subtypes and stratify patients in clinical trials are of high priority.

Funding Details: $150,000-$600,000 based on stage and scope of research. Larger amounts will be considered for PET ligand development for regulatory or clinical work. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. One year with potential for follow-on funding. Multi-year proposals can be considered.

Additional Details
LOI Deadline: Accepted on a rolling basis January 18, April 12, July 12, October 11.
Sponsor Deadline: Accepted on a rolling basis February 8, May 10, August 9, November 8.

McMaster University, McMaster Institute for Research on Aging (MIRA), Canadian Longitudinal Study on Aging (CLSA): Call for Proposals
The CLSA is a large, national, long-term study of more than 50,000 men and women who were between the ages of 45 and 85 when recruited. These participants will be followed until 2033, or death. The aim of the CLSA is to find ways to help us live long and live well, and understand why some people age in healthy fashion while others do not.

Researchers must notify Laura Harrington, Managing Director, MIRA, of their intent to apply for CLSA data access to be considered for MIRA funding. MIRA funds are allocated only to projects that do not have any other funding for this purpose.

MIRA membership is required to be eligible.

Data access applications are accepted three times per year.

Funding Details: MIRA can support access fees of $3,000 for a maximum 10 applications.

Sponsor Deadline: Ongoing

McMaster University, McMaster Institute for Research on Aging (MIRA), Labarge Centre for Mobility in Aging (LCMA): Matching Funds for Research Opportunities
The McMaster Institute for Research on Aging (MIRA) aims to optimize the health and longevity of the aging population through leading-edge research, education and stakeholder collaborations. The institute intends to amplify McMaster’s strength in aging-focused research through stimulating new partnerships, facilitating access to research funding, raising the profile of McMaster’s research platforms, and building capacity among students and faculty members. In order to improve the positioning of McMaster’s researchers in external funding competition, MIRA and the Labarge Centre for Mobility in Aging (LCMA) have allocated funding that could be used to match or leverage external funds. This process is intended to be used for requests related to externally funded, peer-reviewed grant competitions that require a matching component.

Funding Details: Maximum $100,000 (total cash and/or in-kind) non-renewable funding anticipated support 1-2 projects per year.

Additional Details
Sponsor Deadline: Ongoing

MITACS Globalink Research Award
The Mitacs Globalink Research Award provides funding for senior undergraduate and graduate students, and postdoctoral fellows in Canada to conduct 12–24-week research projects at universities overseas. The following opportunities support travel and research from Canada to universities in:

Australia, Brazil, China, EU member countries: In France, both universities and Inria Research Centres are eligible host institutions, Israel, India, Japan, Korea, Mexico, Norway, Saudi Arabia, Tunisia, United Kingdom, United States.
**Funding Details:** $6,000 to conduct 12-24-week research projects at universities overseas.

**Additional Details**
**Sponsor Deadline:** Ongoing

**MITACS Accelerate Fellowship**
The Mitacs Accelerate Fellowship provides a long-term funding and internship option for master’s and PhD students. Recipients can also access professional development training that helps them ensure project success and gain in-demand career skills. Interested applicants can apply for the Accelerate Fellowship at any time. All other Accelerate program guidelines apply.

**Funding Details:**
- **Master’s students** - $40,000 total research award for 18 mos. Minimum intern stipend is $30,000 and partner organization contribution is $18,000
- **PhD students** - $80,000 total research award for 36 mos. Minimum intern stipend is $72,000 (24,000/year) and partner organization contribution is $36,000

**Additional Details**
**Sponsor Deadline:** Ongoing
*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

**Weston Brain Institute: Big Ideas**
Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. If ignored, the social and economic costs of managing these diseases will continue to rise. Meeting these challenges requires pioneering approaches to accelerating treatments.

Based on success of previous programs, the Institute is expanding our support to new formats while maintaining the same mandate of accelerating the developments of therapeutics for neurodegenerative diseases of aging through translational research.

The Institute is considering supporting a large-scale, pivotal project to significantly advance research in our field. With this call, we are seeking to identify highly impactful ideas for consideration. Of particular interest are ideas that will establish Canada as the world leader in a particular area.

**Goal:** To support a large-scale, pivotal project that will significantly and sustainably advance research in the field of translational research on neurodegenerative diseases of aging.

**Funding Details:** From $5,000,000 to $20,000,000.

**Additional Details**
**Sponsor Deadline:** Ongoing

**Weston Brain Institute: Early Phase Clinical Trials: Canada**
Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. If ignored, the social and economic costs of managing these diseases will continue to rise. Meeting these challenges requires pioneering approaches to accelerating treatments. The Early Phase Clinical Trials: Canada program was created to provide funding support for clinical trials and clinical trial sub-studies that have excellent preliminary data. Eligible Principal Applicants must be at or above the level of Assistant Professor or equivalent and be affiliated with a Canada Revenue Agency-qualified donee institution located in Canada. Co-applicants and Collaborators must be at the post-doctoral level or above and can be working outside Canada.

An application requires the submission of a Letter of Intent which will be reviewed by our scientific review committee. Applicants with high potential projects will then be invited to submit a Proposal. Instructions for submitting the Proposal will be forwarded to those invited. Applicants can expect to receive the outcome of their LOI application approximately 2 months after submission.

**Funding Details:** A maximum of $1,500,000 per project over up to 4 years.

**Additional Details**
**Sponsor Deadline:** Ongoing

**OCE Voucher for Innovation and Productivity II (VIP II) Program**
The VIP II program helps established Ontario-based companies develop, implement and commercialize technical innovations by supporting partnerships with publicly-funded post-secondary institutions. Projects funded through VIP II address company needs by enabling the development of new products and/or processes, or facilitating productivity improvements, by leveraging post-secondary institutions’ skills and resources. Projects must ultimately help generate new revenues and create high-value jobs for
Ontario companies. You can also leverage your sponsor’s contribution through the NSERC CRD program for additional research funds.

**Funding Details:** The VIP II program supports collaborations between companies and publicly-funded post-secondary institutions for durations of 12 and 24 months to a maximum of $150,000.

**Additional Details**

**Sponsor Deadline:** Ongoing

*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

---

**MITACS Accelerate Program**

Canada’s premiere research internship program provides interns with the opportunity to transfer their skills from theory to real-world application, while companies gain a competitive advantage by accessing high-quality research expertise. Interns spend approximately half their time on-site with the industry partner; the remainder is spent at the university advancing the research under the guidance of a faculty supervisor. Not-for-profit organizations are eligible.

**Funding Details:** Funding starts at $15,000

**Additional Details**

**Sponsor Deadline:** Ongoing

*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

---

**Department of Defense (DoD) Joint Warfighter Medical Research Program (JWMRP)**

The Joint Warfighter Medical Research Program (JWMRP), managed by the Congressionally Directed Medical Research Programs (CDMRP) at the US Army Medical Research and Materiel Command, provides an opportunity to advance previously funded DoD or Service medical R&D projects that address the medical requirements of the Services. The JWMRP complements and enhances the Defense Health Program by facilitating the further development of promising industry and academic efforts. Each year a broad spectrum of R&D initiatives are considered under the JWMRP. The science and technology development efforts are aligned to one of the six Joint Program Committee (JPC) scientific domains. These are: Medical Simulation and Information Sciences (JPC-1), Military Infectious Diseases (JPC-2), Military Operational Medicine (JPC-5), Combat Casualty Care (JPC-6), Radiation Health Effects (JPC-7), and Clinical and Rehabilitative Medicine (JPC-8). Through research efforts focused in advanced technology development and product demonstration and validation, the JWMRP offers a pathway to transition maturing medical solutions to the Military Health System (MHS) for the benefit of our Service members and other MHS beneficiaries. In accordance with the Congressional language, the funds appropriated for the JWMRP shall be used to augment and accelerate high priority DoD and Service medical requirements and to continue prior year initiatives that are close to achieving their objectives and yield a benefit to military medicine. These funds shall not be used for new projects or for basic research.

**The Fiscal Year 2019 JWMRP has requirements in the following areas:**

**JPC-1/Medical Simulation and Information Sciences Research Program (MSISRP):** The MSISRP manages research programs to explore the implications of models and technology for medical education and for the provision, management, and support of health services in the military. The major research and development focus areas are the following:

Medical Modeling, Simulation, and Training Technologies:
- Combat Casualty Training Initiative: Examine the efficacy of modern simulation system technology vs. current models for advancing combat casualty trauma training
- Medical Readiness Initiative: Medical provider training systems and assessment of competence for sustained military medical readiness
- Tools for Medical Education: Promote medical simulation-related technologies by providing tools for providers to easily develop new products and content
- Health-Focused Initiative: Develop and test self-care technologies that patients use, whenever and wherever they choose, to manage personal health and wellness

Health Informatics and Health Information Technologies:
- Theater/Operational Medicine: Promote, improve, conserve, or restore the mental or physical well-being of personnel through improved health information management and technologies
- Military Healthcare Services: Enhance the efficiency of healthcare operations, ensure the delivery of high-quality healthcare services by improving information accessibility and by providing better decision support for clinicians
- Information Technology (IT) Infrastructure and Data Management: Improve management of health IT and communications infrastructure, healthcare data management, and architecture
Medical Resourcing: Improve the management of healthcare human and financial resources

**JPC-2/Military Infectious Diseases Research Program (MiDRP):** The MiDRP focuses on preventative and therapeutic measures for infectious diseases. These efforts specifically focus on vaccines, anti-parasitic drugs, field-deployable clinical diagnostics (human and vector), prophylactics, and novel therapeutics to treat multidrug-resistant organisms in combat wound infections, as well as vector control pertinent to naturally occurring endemic diseases with demonstrated or potential capability to decrease military operational effectiveness. The major research and development focus areas are the following:

- Novel drug delivery systems
- Novel medical countermeasures and innovative treatment approaches for multidrug-resistant organisms in combat wound infections and/or biofilm formation, maintenance, or propagation
- Treatment options for infectious diseases likely to lead to FDA- licensable, broadly active therapeutics against multiple endemic disease threats

**JPC-5/Military Operational Medicine Research Program (MOMRP):** The MOMRP conducts biomedical research to deliver products and solutions to Service members that address health and fitness throughout the deployment cycle. The major research and development focus areas are the following:

- Injury Prevention and Reduction
- Musculoskeletal Injury
- Psychological Health and Resilience Focused on Decreasing Post-Traumatic Stress Disorder, Depression and Anxiety Disorders, Suicide and Risk Behaviors
- Physiological Health and Performance
- Environmental Health and Protection

**JPC-6/Combat Casualty Care Research Program (CCCRP):** The CCCR provides integrated capabilities for current and future operations to reduce the mortality and morbidity associated with major combat-related trauma across the spectrum of en-route care and facilities-based treatment. A primary emphasis of the CCCR is to identify and develop medical techniques and materiel (medical devices, drugs, and biologics) for early intervention in life-threatening battle injuries and Prolonged Field Care. The major research and development focus areas are the following:

- Forward Surgical Critical Intensive Care
- En-Route Care
- Hemorrhage Control & Resuscitation
- Neurotrauma/Traumatic Brain Injury
- Military Medical Photonics

**JPC-7/Radiation Health Effects Research Program (RHERP):** The RHERP focuses on developing countermeasures for acute ionizing radiation injury. The major research and development focus areas are the following:

- Post-exposure mitigation of radiation injury
- Protection and prevention of injury from ionizing radiation exposure (prophylaxis)
- Development of novel radiation biodosimetry tools

**JPC-8/ Clinical and Rehabilitative Medicine Research Program (CRMRP):** The CRMRP focuses on the innovations required to reset our wounded Service members, both in terms of duty performance and quality of life. Innovations developed from CRMRP-supported research efforts are expected to improve restorative treatments and rehabilitative care to maximize function for return to duty or civilian life. The major research and development focus areas are the following:

- Neuromusculoskeletal Injury Rehabilitation
- Vision Restoration and Rehabilitation
- Hearing Restoration and Hearing Loss Rehabilitation
- Balance Disorders and Tinnitus
- Pain Management
- Regenerative Medicine and Composite Tissue Engineering

**Funding Details:** TBD

**Additional Details**

**LOI Deadline:** Feb 1, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** TBD

**Sponsor Deadline:** TBD
Department of Defense (DoD) Peer Reviewed Medical Research Program (PRMRP): Discovery Award

The intent of the PRMRP Discovery Award is to support innovative, non-incremental, high-risk/potentially high-reward research that will provide new insights, paradigms, technologies, or applications. Studies supported by this award are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on a sound scientific rationale and study design. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. Innovation is the most important review criterion. Innovative research may introduce a new paradigm, look at existing problems from new perspectives, or exhibit other highly creative qualities. Research that represents an incremental advancement on previously published work is not considered innovative. The following list, although not all-inclusive, provides examples of research that is not innovative:

- Exploring a previously tested hypothesis in a different cell line or in a new population
- Using a published series of in-vitro assays to further characterize a model system
- Incorporating known biomarkers into in-vivo or clinical models of the disease or condition
- Investigating the next logical step or continuation of a previous research project
- Proposing work that is an incremental advancement of published data

Inclusion of preliminary data is not required, but is allowed. The strength of the proposed research should be based on sound scientific rationale and logical reasoning. The presentation of substantial preliminary data suggests that the proposed research project would be more appropriately submitted to a different award mechanism. The outcome of research supported by this award should be the generation of robust preliminary data that can be used as a foundation for future research projects. Absence of preliminary data will not negatively affect scientific or programmatic review of the application.

Funding Details: The anticipated direct costs budgeted for the entire period of performance for an FY19 PRMRP Discovery Award will not exceed $200,000.

Additional Details
LOI Deadline: March 28, 2019 (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: March 28, 2019
Sponsor Deadline: April 11, 2019

Department of Defense (DoD) Peer Reviewed Medical Research Program (PRMRP): Clinical Trial Award

The PRMRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on a disease or condition addressed in at least one of the Congressionally directed FY19 PRMRP Topic Areas. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, Phase 0), to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.

Funding from this award mechanism must support a clinical trial and cannot be used for preclinical research studies. A clinical trial is defined as a prospective accrual of human subjects in whom an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested for a measurable outcome with respect to safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the subject of that intervention or interaction. The term “human subjects” is used in this Program Announcement to refer to individuals who will be recruited for or who will participate in the proposed clinical trial. For more information, a Human Subject Resource Document is provided at https://ebrap.org/eBRAP/public/Program.htm. Principal Investigators (PIs) seeking funding for a preclinical research project should consider one of the other FY19 PRMRP Program Announcements being offered.

If the proposed clinical trial involves the use of a drug that has not been approved by the U.S. Food and Drug Administration (FDA) for the proposed investigational use, then an Investigational New Drug (IND) application to the FDA that meets all requirements under the Code of Federal Regulations, Title 21, Part 312 (21 CFR 312) may be required. It is the responsibility of the applicant to provide evidence from the Institutional Review Board (IRB) of record or the FDA if an IND is not required. If an IND is required, an active IND deemed safe to proceed that covers the proposed trial must be in place by the PRMRP Clinical Trial Award application submission deadline. The IND should be specific for the product (i.e., the product should not represent a derivative or alternate version of the investigational agent described in the IND application) and indication to be tested in the proposed clinical trial. For more information on IND applications, the FDA has provided guidance at
If the investigational product is a device, then an Investigational Device Exemption (IDE) application to the FDA that meets all requirements under 21 CFR 812 may be required. It is the responsibility of the applicant to provide evidence from the IRB of record or the FDA if an IDE is not required, or if the device qualifies for an abbreviated IDE. If an IDE is required, an active IDE deemed safe to proceed that covers the proposed trial must be in place by the PRMRP Clinical Trial Award application submission deadline. The IDE should be specific for the device (i.e., should not represent a derivative or modified version of the device described in the IDE application) and indication to be tested in the proposed clinical trial.

If the clinical trial of an investigational product will be conducted at international sites, evidence is required that an approval from the relevant national regulatory agency of the host country(ies) has been received by the PRMRP Clinical Trial Award application submission deadline. Refer to Attachment 13, Regulatory Strategy, for additional details on documentation of FDA applications. The Government reserves the right to withdraw the application if an active IND or IDE and/or international regulatory approval is necessary but is not in place prior to the application submission deadline.

**Funding Details:** The CDMRP expects to allot approximately $58.5M to fund approximately 9 Clinical Trial Award applications. Funding of applications received is contingent upon the availability of Federal funds for this program as well as the number of applications received, the quality and merit of the applications as evaluated by scientific and programmatic review, and the requirements of the Government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY19 funding opportunity will be funded with FY19 funds, which will expire for use on September 30, 2025.

**Additional Details**

**LOI Deadline:** March 14, 2019 (A pre-application is required and must be submitted through eBRAP)

**Internal HRS Deadline:** June 18, 2019

**Sponsor Deadline:** July 2, 2019

### Department of Defense (DoD) Peer Reviewed Medical Research Program (PRMRP): Focused Program Award

The PRMRP Focused Program Award mechanism is intended to optimize research and accelerate solutions to a critical question related to at least one of the Congressionally directed FY19 PRMRP Topic Areas through a synergistic, multidisciplinary research program.

**Key aspects of this award include:**

**Overarching Challenge:** Focused Program Award applications must describe a unifying, overarching challenge that will be addressed by a set of research projects. The overarching challenge must be relevant to a critical problem or question in the field of research and/or patient care in at least one of the FY19 PRMRP Topic Areas.

**Research Projects:** Applications shall include multiple, distinct research projects led by individual project leaders that address complementary aspects of the overarching challenge. Applicants are strongly encouraged to submit a minimum of four research projects; additional studies are allowed. While individual projects must be capable of standing on their own high scientific merits, they must also be interrelated and synergistic with the other proposed projects and advance a solution beyond what would be possible through individual efforts. The exploration of multiple hypotheses or viewpoints of the same line of questioning is encouraged. This award mechanism is not intended to support a series of research projects that are dependent on the success of any other project. Each project should propose a unique approach to addressing the overarching challenge and be capable of producing research findings with potential to impact the field and/or patient care. Individual research projects may range from exploratory, hypothesis-developing studies through small-scale clinical trials (i.e., up to and including Phase II or equivalent). There should be a clear intent to progress toward translational/clinical work over the course of the effort.

**Implementation:** The research strategy to address the overarching challenge must be supported by a detailed implementation plan that identifies critical milestones; and outlines the knowledge, resources, and technical innovations that will be utilized to achieve the milestones. A robust statistical plan and statistical expertise should be included where applicable. A plan for assessing individual project performance and progress toward addressing the overarching challenge must be included in the implementation plan. Plans to include an External Advisory Board (EAB) are encouraged; however, applicants must be careful to avoid potential conflicts of interest (COIs) during review of the application by ensuring no contact with, recruiting of, or naming of specific EAB members in the application. For multi-institutional collaborations, plans for communication and data transfer among the collaborating institutions, as well as how data, specimens, and/or imaging products obtained during the study will be handled, must be included. An intellectual and material property plan agreed to by participating organizations is required in the application’s supporting documentation.
Research Team: The overall effort will be led by a Principal Investigator (PI) with demonstrated success in leading large, focused projects. The PI is required to devote a minimum DoD FY19 Peer Reviewed Medical Focused Program Award 6 of 20% effort to this award. The PI should create an environment that fosters and supports collaboration and innovation in a way that engages all members of the team in all aspects of the research plan. The research team assembled by the PI should be highly qualified and multidisciplinary, with identified project leaders for each of the complementary and synergistic research projects. The resources and expertise brought to the team by each project leader should combine to create a robust, synergistic collaboration. The PRMRP Science Officer assigned to a resulting award must be invited to participate in research team meetings such as annual meetings of the entire research team. The plan for such meetings should be noted in the application.

Milestone Meeting: The PI will be required to present an update on progress toward accomplishing the goals of the award at a Milestone Meeting to be held in the National Capital Area after the conclusion of Year 2 of the period of performance. The PI may bring up to three additional members of the research team to the meeting. The Milestone Meeting will be attended by members of the PRMRP Programmatic Panel, CDMRP staff, and the USAMRAA Grants Officer.

Funding Details: The anticipated direct costs budgeted for the entire period of performance for an FY19 PRMRP Focused Program Award will not exceed $7.2M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Additional Details
LOI Deadline: March 14, 2019 (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: June 18, 2019
Sponsor Deadline: July 2, 2019

**Department of Defense (DoD) Peer Reviewed Medical Research Program (PRMRP): Investigator-Initiated Research Award**

The PRMRP Investigator-Initiated Research Award (IIRA) is intended to support studies that will make an important contribution toward research and/or patient care for a disease or condition related to at least one of the FY19 PRMRP Topic Areas.

The rationale for a research idea may be derived from a laboratory discovery, population-based studies, a clinician’s first-hand knowledge of patients, or anecdotal data. Applications must include relevant data that support the rationale for the proposed study. These data may be unpublished or from the published literature.

Impact: The Investigator-Initiated Research Award is designed to support research with the potential to yield highly impactful data that could lead to critical discoveries or major advancements. The application must clearly demonstrate the project’s potential immediate and long-range outcome(s)/product(s) (knowledge and/or materiel) and how they will impact a central critical problem or question in the field of research and/or patient care in the FY19 PRMRP Topic Area(s) addressed.

Research projects may focus on any phase of research from basic laboratory research through translational research, including preclinical studies in animal models and human subjects, as well as correlative studies associated with an existing clinical trial. Research involving human subjects and human anatomical substances is permitted; however, this award may not be used to conduct clinical trials. A clinical trial is defined as a prospective accrual of patients (human subjects) in whom an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested for a measurable outcome with respect to safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the subject of that intervention or interaction. For more information on how to distinguish clinical research from clinical trials, see the Human Subject Resource Document at https://ebrap.org/eBRAP/ public/Program.htm. Principal Investigators (PIs) seeking funding for a clinical trial should apply to the FY19 PRMRP Clinical Trial Award mechanism (Funding Opportunity Number: W81XWH-19-PRMRP-CTA).

Funding Details: The anticipated direct costs budgeted for the entire period of performance for a single PI FY19 PRMRP IIRA award will not exceed $1.2M. The anticipated direct costs budgeted for the entire period of performance for an FY19 PRMRP IIRA award with the Partnering PI Option will not exceed $1.5M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Additional Details
LOI Deadline: March 14, 2019 (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: June 27, 2019
Sponsor Deadline: July 11, 2019

**Department of Defense (DoD) Peer Reviewed Medical Research Program (PRMRP): Technology/Therapeutic Development Award**

The PRMRP Technology/Therapeutic Development Award (TTDA) is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis,
treatment, or quality of life, in at least one of the Congressionally directed FY19 PRMRP Topic Areas. Products in development should be responsive to the healthcare needs of military Service members, Veterans, and/or beneficiaries.

The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product. A “Knowledge Product” is a non-materiel product that addresses an identified need in a Topic Area, is based on current evidence and research, aims to transition into medical practice, training, tools, or to support materiel solutions (systems to develop, acquire, provide, and sustain medical solutions and capabilities), and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes. The Principal Investigator (PI) must provide a transition plan (including potential funding and resources, see Attachment 8) showing how the product will progress to the next level of development (e.g., clinical trials, delivery to the military or civilian market) after the completion of the PRMRP award. PIs are encouraged to develop relationships with industry and/or other funding agencies to facilitate moving the product into the next phase of development.

Proof-of-concept demonstrating the potential utility of the proposed product, or a prototype/preliminary version of the proposed product, should already be established. Applications must include relevant data that support the rationale for the proposed study. These data may be unpublished and/or from the published literature. Investigators seeking to identify a product or demonstrate initial proof-of-concept should consider submitting to the FY19 PRMRP Investigator-Initiated Research Award (Funding Opportunity Number: W81XWH-19-PRMRP-IIRA) or the FY19 PRMRP Discovery Award (Funding Opportunity Number: W81XWH-19-PRMRP-DA), as appropriate.

- Examples of the types of research that may be supported include, but are not limited to:
  - Developing and validating clinical guidance/guidelines for standard of care
  - Testing new therapeutic modalities (agents, delivery systems, and chemical modification of lead compounds) using established or validated preclinical systems
  - Designing and implementing pilot or full-scale Good Manufacturing Practice (GMP) production of therapeutics and/or delivery systems for use in advanced preclinical and initial clinical trials
  - Developing pharmacologic agents through absorption, distribution, metabolism, excretion, and toxicity (ADMET) studies
  - Developing pharmacologic agents to Investigational New Drug (IND) stage for initiation of Phase I clinical trials
  - Developing prototype devices to Investigational Device Exemption (IDE) stage or abbreviated IDE stage for initiation of clinical trials
  - Optimizing diagnostic or treatment devices for field deployment

**Funding Details:** The anticipated direct costs budgeted for the entire period of performance for an FY19 PRMRP TTDA award will not exceed $3M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

**Additional Details**

**LOI Deadline:** March 14, 2019 (A pre-application is required and must be submitted through eBRAP)
**Internal HRS Deadline:** June 27, 2019
**Sponsor Deadline:** July 11, 2019

---

**Department of Defense (DoD) Amyotrophic Lateral Sclerosis Research Program (ALSRP): Therapeutic Development Award**

The Therapeutic Development Award supports research ranging from validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited ALS experience are strongly encouraged to collaborate with those having substantial expertise in ALS research and/or ALS model systems. Examples of activities that will be supported by this award include:

- Confirmation of candidate therapeutics obtained from screening or by other means, including optimization of potency and pharmacological properties and testing of derivatives and sister compounds
- Validation of early pilot studies, including the use of multiple ALS model systems and/or replicating preliminary data with more time points or additional doses
- Studies on formulation and stability leading to Good Manufacturing Practice (GMP) production methods
- IND-enabling studies, to include compound characterization, absorption, distribution, metabolism, and excretion (ADME) studies, and dose/response and toxicology studies in relevant model systems

**Funding Details:**

- The anticipated direct costs budgeted for the entire period of performance will not exceed $1,250,000. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. No budget
will be approved by the Government exceeding $1,250,000 direct costs or using an indirect cost rate exceeding the organization’s negotiated rate.

- A Therapeutic Development Award application including Therapeutically Relevant Marker Option that does not meet the criteria specified for that option may be funded at the lower maximum direct costs of $1,000,000, i.e., at the level of the standard Therapeutic Development Award as described above.

All direct and indirect costs of any subaward or contract must be included in the total direct costs of the primary award. The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 2 years.

**Additional Details**

**LOI Deadline: March 22, 2019 (A pre-application is required and must be submitted through eBRAP)**

**Internal HRS Deadline: July 11, 2019**

**Sponsor Deadline: July 25, 2019**

---

**Department of Defense (DoD) Amyotrophic Lateral Sclerosis Research Program (ALSRP): Therapeutic Idea Award**

The Therapeutic Idea Award is designed to promote new ideas aimed at drug or treatment discovery that are still in the early stages of development. Projects that focus primarily on investigating the pathophysiology of ALS are not within the scope of this Funding Opportunity. Development and/or modification of preclinical model systems or the application of high-through-put screens to define or assess lead compounds for ALS treatment are of interest. Development of methods to adequately measure target binding and proximal downstream effects (target engagement) and the potential for undesirable activities at related but unintended targets (selectivity) are also encouraged. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data, but on the innovative approach. All proposed research projects should include a well-formulated, testable hypothesis based on strong scientific rationale that holds translational potential to improve ALS treatment and/or advance a novel treatment modality.

Innovation and impact are important aspects of the Therapeutic Idea Award. Research deemed innovative may introduce a new paradigm, challenge current paradigms, introduce novel concepts or technologies, or exhibit other uniquely creative qualities that may lead to potential therapeutics for ALS. Impact may be near-term or long-term, but must be significant and move beyond an incremental advancement.

**Funding Details:** The maximum period of performance is 2 years. The anticipated direct costs budgeted for the entire period of performance will not exceed $500,000. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. No budget will be approved by the Government exceeding $500,000 direct costs or using an indirect cost rate exceeding the organization’s negotiated rate.

**Additional Details**

**LOI Deadline: March 22, 2019 (A pre-application is required and must be submitted through eBRAP)**

**Internal HRS Deadline: July 11, 2019**

**Sponsor Deadline: July 25, 2019**